Attenuation of the Wnt/β-catenin/TCF pathway by in vivo interferon-α2b (IFN-α2b) treatment in preneoplastic rat livers

Growth Factors

Volumn 28, Issue 3, 2010, Pages 166-177

  Parody, Juan P ^a   Alvarez, Maria L ^a   Quiroga, Ariel D ^a   Ceballos, Maria P ^a   Frances, Daniel E ^a   Pisani, Gerardo B ^b   Pellegrino, Jose M ^a   Carnovale, Cristina E ^a   Carrillo, Maria C ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

catenin; FOXO; Hepatocarcinogenesis; Oxidative stress; TCF

Indexed keywords

ALPHA2B INTERFERON; BETA CATENIN; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR FOXO; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DRUG MECHANISM; EARLY CANCER; IN VIVO STUDY; LIVER CARCINOGENESIS; MALE; NONHUMAN; OXIDATIVE STRESS; PRECANCER; PRIORITY JOURNAL; RAT;

ANIMALS; APOPTOSIS; BETA CATENIN; HUMANS; INTERFERON ALFA-2B; LIVER NEOPLASMS, EXPERIMENTAL; MALE; PRECANCEROUS CONDITIONS; RATS; RATS, WISTAR; TCF TRANSCRIPTION FACTORS; WNT PROTEINS;

RATTUS;

EID: 77952525742     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977190903547863     Document Type: Article

References (54)

1. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. 1997. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16:3797-3804.
2. Alvarez ML, Quiroga AD, Parody JP, Ronco MT, Frances DE, Carnovale CE, Carrillo MC. 2009. Cross-talk between IFN-alpha and TGF-beta1 signaling pathways in preneoplastic rat liver. Growth Factors 27:1-11.
3. Behrens J, Jerchow BA, Wũrtele M, Grimm J, Asbrand C, Wirtz R, Kũhl M, Wedlich D, Birchmeier W. 1998. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280:596-599.
4. Bellan C, De Falco G, Tosi GM, Lazzi S, Ferrari F, Morbini G, Bartolomei S, Toti P, Mangiavacchi P, Cevenini G, Trimarchi C, Cinti C, Giordano A, Leoncini L, Tosi P, Cottier H. 2002. Missing expression of pRb2/p130 in human retinoblastomas is associated with reduced apoptosis and lesser differentiation. Invest Ophthalmol Vis Sci 43:3602-3608.
5. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. 1999. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 155:1033-1038.
6. Bruix J, Boix L, Sala M, Llovet JM. 2004. Focus on hepatocellular carcinoma. Cancer Cell 5:215-219.
7. Burgering BM, Kops GJ. 2002. Cell cycle and death control: Long live forkheads. Trends Biochem Sci 27:352-360.
8. Cadigan KM, Nusse R. 1997. Wnt signaling: A common theme in animal development. Genes Dev 11:3286-3305.
9. Calvisi DF, Factor VM, Loi R, Thorgeirsson SS. 2001. Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: Relationship to phenotype and tumor grade. Cancer Res 61:2085-2091.
10. Cavallo RA, Cox RT, Moline MM, Roose J, Polevoy GA, Clevers H, Peifer M, Bejsovec A. 1998. Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 395:604-608.
11. Devereux TR, Anna CH, Foley JF, White CM, Sills RC, Barrett JC. 1999. Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. Oncogene 18:4726-4733.
12. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. 2000. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10:1201-1204.
13. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC. 2005. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308:1181-1184.
14. 5. J Biol Chem 282:1225-1237.
15. Furukawa-Hibi Y, Kobayashi Y, Chen C, Motoyama N. 2005. FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal 7:752-760.
16. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. 2007. Cyclin D1 in non-small cell lung cancer: A key driver of malignant transformation. Lung Cancer 55:1-14.
17. Gutterman JU. 1994. Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci USA 91:1198-1205.
18. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. 1998. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 8:573-581.
19. Hoogeboom D, Essers MA, Polderman PE, Voets E, Smits LM, Burgering BM. 2008. Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity. J Biol Chem 283:9224-9230.
20. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, Koida I, Arase Y, Chayama K, Murashima N, Kumada H. 1998. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study. Cancer 82:827-835.
21. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. 2002. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22:1172-1183.
22. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV, Korc M. 1999. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 59:3505-3511.
23. Levanon D, Goldstein RE, Bernstein Y, Tang H, Goldenberg D, Stifani S, Paroush Z, Groner Y. 1998. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci USA 95:11590-11595.
24. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X. 2002. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108:837-847.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
26. Mao J, Wang J, Liu B, Pan W, Farr GH 3rd, Flynn C, Yuan H, Takada S, Kimelman D, Li L, Wu D. 2001. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell 7:801-809.
27. Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, Kew MC, Trepo C, Wands JR. 2004. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 127:1110-1122.
28. Merle P, Kim M, Herrmann M, Gupte A, Lefrançois L, Califano S, Trépo C, Tanaka S, Vitvitski L, de la Monte S, Wands JR. 2005. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol 43:854-862.
29. Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T, Nakamura Y. 1998. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 58:2524-2527.
30. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. 1997. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787-1790.
31. Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J Clin 55:74-108.
32. Parody JP, Alvarez ML, Quiroga A, Ronco MT, Frances D, Carnovale C, Carrillo MC. 2007. Hepatocytes isolated from preneoplastic rat livers are resistant to ethacrynic acid cytotoxicity. Arch Toxicol 81:565-573.
33. Pfeffer LM. 1997. Biologic activities of natural and synthetic type I interferons. Semin Oncol 24:S9.
34. Pitot HC. 1990. Altered hepatic foci: Their role in murine hepatocarcinogenesis. Annu Rev Pharmacol Toxicol 30:465-500.
35. Powell WC, Knox JD, NavreM, Grogan TM, Kittelson J, Nagle RB, Bowden GT. 1993. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 53:417-422.
36. Quiroga AD, Alvarez ML, Parody JP, Ronco MT, Frances DE, Pisani GB, Carnovale CE, Carrillo MC. 2007. Involvement of reactive oxygen species on the apoptotic mechanism induced by IFN-alpha2b in rat preneoplastic liver. Biochem Pharmacol 73:1776-1785.
37. Quiroga AD, de Lujan Alvarez M, Parody JP, Ronco MT, Carnovale CE, Carrillo MC. 2009. Interferon-alpha2b (IFN-alpha2b) -induced apoptosis is mediated by p38 MAPK in hepatocytes from rat preneoplastic liver via activation of NADPH oxidase. Growth Factors 27.
38. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. 1997. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790-1792.
39. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Zéev A. 1999. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96:5522-5527.
40. Tamai K, Semenov M, 1Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet JP, He X. 2000. LDL-receptor-related proteins in Wnt signal transduction. Nature 407:530-535.
41. Tanaka Y, Kato K, Notohara K, Hojo H, Ijiri R, Miyake T, Nagahara N, Sasaki F, Kitagawa N, Nakatani Y, Kobayashi Y 2001. Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid- pseudopapillary neoplasm. Cancer Res 61:8401-8404.
42. Thorgeirsson SS, Grisham JW. 2002. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339-346.
43. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. 2002. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2:8.
44. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. 1997. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 94:1402-1407.
45. Yamamoto H, Itoh F, Hinoda Y, Imai K. 995. Suppression of matrilysin inhibits colon cancer cell invasion in vitro. Int J Cancer 61:218-222.
46. Yanagawa S, van Leeuwen F, Wodarz A, Klingensmith J, Nusse R. 1995. The dishevelled protein is modified by wingless signaling in Drosophila. Genes Dev 9:1087-1097.
47. Yanagawa S, Matsuda Y, Lee JS, Matsubayashi H, Sese S, Kadowaki T, Ishimoto A. 2002. Casein kinase I phosphorylates the Armadillo protein and induces its degradation in Drosophila. EMBO J 21:1733-1742.
48. Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, Sakamoto D, Caothien RH, Fuller JH, Reinhard C, Garcia PD, Randazzo FM, Escobedo J, Fantl WJ, Williams LT. 2001. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci USA 98:14973-14978.
49. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M. 1999. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 131:174-181.
50. Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry WL 3rd, Lee JJ, Tilghman SM, Gumbiner BM, Costantini F. 1997. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 90:181-192.
51. Zurita M, Cabrera MM, Morales C, Oya S, Vaquero J. 1994. Influence of the postnatal administration of tumor necrosis factor plus interferon-alpha 2b on the development of ethylnitrosourea-induced brain tumors in rats. Neurosci Lett 174:213-216.
52. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C. 1998. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95:8847-8851.
53. de Luján Alvarez M, Cerliani JP, Monti J, Carnovale C, Ronco MT, Pisani G, Lugano MC, Carrillo MC. 2002. The in vivo apoptotic effect of interferon alfa-2b on rat preneoplastic liver involves Bax protein. Hepatology 35:824-833.
54. de Luján Alvarez M, Ronco MT, Ochoa JE, Monti JA, Carnovale CE, Pisani GB, Lugano MC, Carrillo MC. 2004. Interferon alpha-induced apoptosis on rat preneoplastic liver is mediated by hepatocytic transforming growth factor beta (1). Hepatology 40:394-402.